Linda

Navient recognized by Women’s Forum of New York as a “Corporate Champion” for gender diversity

Retrieved on: 
Wednesday, November 8, 2023
Linda, Female, Corporation, Fortune 1000, Breakfast, Woman, NAVI, Boilermaker

HERNDON, Va., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Navient (Nasdaq: NAVI), a leader in technology-enabled education finance and business processing solutions, is proud to announce that it has been recognized as a Corporate Champion by Women’s Forum of New York.

Key Points: 
  • HERNDON, Va., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Navient (Nasdaq: NAVI), a leader in technology-enabled education finance and business processing solutions, is proud to announce that it has been recognized as a Corporate Champion by Women’s Forum of New York.
  • Navient, which has four women on its nine-member board, was honored at the Women’s Forum of New York’s seventh biennial Breakfast of Corporate Champions, which celebrated 233 companies in the S&P 500 and Fortune 1000 that have achieved at least 40% female representation on their boards.
  • “Promoting diversity and inclusion at all levels broadens our perspectives and equips us to reach our highest potential,” said Linda Mills, chair of Navient’s Board of Directors, who represented the company at the event.
  • “We’re pleased to be among the distinguished companies honored today who are promoting greater gender diversity in the boardroom and beyond.”

KORU Medical Systems, Inc. Announces Development Agreement for Next-generation Subcutaneous Immunoglobulin Infusion System

Retrieved on: 
Wednesday, November 8, 2023
Biotechnology, Medical Devices, Health, Pharmaceutical, Medical Supplies, Linda, Pharmacy, Quality of life, KORU, KRMD, FDA, Patient, Therapy, Life, Medical device

KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced a development agreement with a biopharmaceutical manufacturer for KORU Medical to develop and seek regulatory approval for a next-generation infusion system for its subcutaneous immunoglobulin (SCIg) therapy.

Key Points: 
  • KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced a development agreement with a biopharmaceutical manufacturer for KORU Medical to develop and seek regulatory approval for a next-generation infusion system for its subcutaneous immunoglobulin (SCIg) therapy.
  • “This collaboration is another milestone in our strategy to provide the best infusion experience to SCIg patients,” said Linda Tharby, KORU Medical’s President and CEO.
  • KORU Medical has been the first to receive FDA 510(k) clearance for every new SCIg drug approved since 2020.
  • We’re excited to collaborate with a biopharmaceutical company on this new innovative infusion system.”

KORU Medical Systems, Inc. Appoints Ken Miller as Chief Commercial Officer

Retrieved on: 
Wednesday, November 8, 2023
Pharmaceutical, Health, Medical Supplies, Medical Devices, Linda, KRMD, Worldwide, Security (finance), NYSE, International, Compensated emancipation, Life, Master of Business Administration, University of Chicago, Laboratory, EBITDA, Roche, Novo Nordisk, Cyprus Securities and Exchange Commission, Organization, Reckitt, NASCO, University of Chicago Booth School of Business, Quality of life, Growth, BDX, Business administration, Marketing, Employment, Business, State university system, University, BD (company), Chief commercial officer, Patient, State University of New York, Pharmaceutical industry, Management

KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023.

Key Points: 
  • KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced the appointment of Ken Miller as Chief Commercial Officer, effective November 6, 2023.
  • As Chief Commercial Officer, Ken will have oversight of the global commercial function including U.S. and International sales and marketing organizations.
  • He joins KORU Medical with impressive medical device and pharmaceutical industry experience, most recently from NASCO Healthcare where he spent five years as President & CEO.
  • Ken also held leadership roles in marketing, sales, and business development with Novo Nordisk, Adams Respiratory Therapeutics, and Roche Laboratories.

KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60® Infusion System With Hizentra® 50 ML Prefilled Syringes

Retrieved on: 
Tuesday, November 7, 2023
Other Health, Health, Pharmaceutical, Managed Care, Medical Supplies, Linda, KRMD, FDA, Food, PFS, PIDD, Quality of life, KORU, Therapy, CSL Behring, CIDP, Syringe, Patient, Food and Drug Administration, Medical device, Pharmaceutical industry

“Being the first and only FDA-cleared infusion system for use with prefilled syringes demonstrates KORU Medical’s continued commitment to enhance the patient experience for all patients self-administering subcutaneous immunoglobulin (SCIg) therapy in the home,” said Linda Tharby, KORU Medical’s President and CEO.

Key Points: 
  • “Being the first and only FDA-cleared infusion system for use with prefilled syringes demonstrates KORU Medical’s continued commitment to enhance the patient experience for all patients self-administering subcutaneous immunoglobulin (SCIg) therapy in the home,” said Linda Tharby, KORU Medical’s President and CEO.
  • We are now able to deliver PFS benefits to Hizentra® patients through our FREEDOM™ Infusion System portfolio - the FREEDOM60® Infusion System with 50 mL PFS and the FreedomEdge® with 20 mL PFS.
  • When using prefilled syringes with the FREEDOM™ Infusion System, KORU Medical has demonstrated that patients can experience up to an 80% reduction in drug preparation tasks when compared to using vials.
  • The FDA approved the Hizentra® 50 mL prefilled syringe in April 2023, and CSL Behring has announced an early 2024 availability.

Syniti Announces Strong Third Quarter 2023 Results Propelled by Data First Strategy

Retrieved on: 
Tuesday, November 7, 2023
Cloud, Knowledge, Linda, Carbon, Female, Woman, Lion, Carbon Disclosure Project, ARR, SKP, Organon, Synthetic media, Merck, Generative, ACV, APJ, Data management, Stevie Awards, Growth, Marketing, SAP, HR, SAP Solution Manager, OpenAI, CFO, Success, Foodservice, Music, Cryptocurrency, Management, Information technology

BOSTON, Nov. 7, 2023 /PRNewswire/ -- Syniti, a global leader in enterprise data management, today announced key financial and company highlights for the third quarter of 2023. New and repeat customers are responding to Syniti's Data First strategy which advocates the importance of starting data alongside or even before global design during digital and business transformation efforts. As businesses realize that "good enough" shouldn't apply to the quality of their data, they continue to ask Syniti and its team of data experts to take a principal role in leading the crucial stages of their transformation projects.

Key Points: 
  • New and repeat customers are responding to Syniti's Data First strategy which advocates the importance of starting data alongside or even before global design during digital and business transformation efforts.
  • Syniti added 10 significant new logos in the quarter, expanding its client base globally and deepening its expertise with Global2000 oil & gas and aerospace & defense enterprises.
  • Syniti closed its highest quarter ever in license volume with SAP, underpinning the importance of data in driving digital transformation with SAP S/4HANA Cloud.
  • Syniti has leveraged its own Rapid Data Governance solution framework to create this series of prepackaged, custom objects to accelerate data governance activities across various SAP Master Data Governance domains.

Matt Zemon to Host Transformative Stories Panel at Wonderland Conference

Retrieved on: 
Thursday, November 2, 2023
Linda, Science, Transformation Story Archive, Anxiety, Trip, Consciousness, Policy, FOR, Psychedelic drug, Conference, Master, Spirit, PTSD, Muslims, MSC, King's College London, Beginner, Master of Science, Imperial College London, Integration, Addiction, Fierce Hearts, Longevity, Mental health, Management, Nightclub, Courage, Depression

Miami, Florida--(Newsfile Corp. - November 2, 2023) - The upcoming Wonderland Conference, renowned for its innovative discourse on psychedelic medicine, longevity, and mental health, will feature a panel led by Matt Zemon, MSc on November 10th at 5:00 PM at The Explore Stage.

Key Points: 
  • Miami, Florida--(Newsfile Corp. - November 2, 2023) - The upcoming Wonderland Conference, renowned for its innovative discourse on psychedelic medicine, longevity, and mental health, will feature a panel led by Matt Zemon, MSc on November 10th at 5:00 PM at The Explore Stage.
  • Titled "Transformative Stories," the panel seeks to share and "normalize" the sharing of personal journeys within the realm of psychedelic experiences, emphasizing the therapeutic and transformative aspects of these powerful and ancient medicines.
  • Tracey Tee: The trailblazing founder of Moms on Mushrooms, Tracey's transformative journey from adversities to advocacy has made national headlines.
  • For more information about this session or to register for the conference, visit the Wonderland Conference website .

Consolidated Water Group Acquires Ramey Environmental Compliance, Broadening Presence in Water-Stressed Western U.S.

Retrieved on: 
Monday, November 6, 2023
Linda, Consolidated, PERC, Water, REC, Acquisition, Maintenance, United, GEORGE, EPA, Rocky Mountains, Electric power

REC specializes in helping municipalities and districts comply with environmental regulations and properly manage their precious water resources through a variety of service offerings.

Key Points: 
  • REC specializes in helping municipalities and districts comply with environmental regulations and properly manage their precious water resources through a variety of service offerings.
  • REC currently services more than 100 water and wastewater treatment customers.
  • This acquisition provides a new channel for PERC to expand its existing footprint into additional water-stressed regions across Colorado.
  • Additional details about the definitive stock purchase agreement are provided in a Form 8-K, available at www.sec.gov and the Investors section of Consolidated Water’s website at cwco.com .

Research Funded by Bay Area Lyme Foundation Identifies New Investigational Therapy Regimen Capable of Irreversibly Damaging Lyme Bacteria in Laboratory Tests

Retrieved on: 
Wednesday, November 1, 2023
Linda, Knowledge, Lyme disease, University of California, Davis, Stanford University, Infection, UC, Obesity, MD, University of North Carolina, Doctor of Philosophy, Research, Light, Protein, Duke University School of Medicine, Borrelia burgdorferi, Medicine, Hypertension, Immunotherapy, Bacteria, University, Cell Chemical Biology, Cancer, Hsp90, Cell wall, Patient, Tulane University, DNA, Fatigue, Pharmaceutical industry, Vaccine, Pharmacology

“Bay Area Lyme concentrates on funding innovative research, including projects where knowledge can be deployed from other areas of medicine.

Key Points: 
  • “Bay Area Lyme concentrates on funding innovative research, including projects where knowledge can be deployed from other areas of medicine.
  • He encouraged scientists to take cancer staging techniques and immunotherapy learnings from oncology and apply them to Lyme research.
  • Bay Area Lyme Foundation also funded University of North Carolina collaborator, Matt Redinbo , PhD’s research on HS-291; his lab’s crystallography work was instrumental in the discovery process.
  • Bay Area Lyme Foundation’s research grant program was made possible by the support from the Fairbairn Family, the Younger Family Fund, and Project Lyme .

Announcing Keynote Lineup: Leading Voices in Cybersecurity, Tech, and Leadership to Headline at EWF 2023 Annual Conference

Retrieved on: 
Monday, October 30, 2023
Linda, Knowledge, Risk, Female, Woman, Policy, Woolley, Ecosystem, Ethics, Government, Canadian Undergraduate Technology Conference, Bain, United States Air Force, Courage, McGuire family, Conference, Merck, Doctor of Philosophy, Bain & Company, Control, The Future of Money, Risk management, CISO, Annual conferences within Methodism, Asian Leadership Conference, Executive, KC, Campbell, Face, IBM, EWF, Medical device, Fear, Privacy, AI

Every year the Executive Women’s Forum on Information Security, Risk Management & Privacy (EWF) selects a few women at the forefront of leadership and technology to deliver keynote speeches at their Annual Conference.

Key Points: 
  • Every year the Executive Women’s Forum on Information Security, Risk Management & Privacy (EWF) selects a few women at the forefront of leadership and technology to deliver keynote speeches at their Annual Conference.
  • This year's conference, Blazing the Trail: Technology and Leadership in Complex Times , on November 7-9 in San Antonio, TX, will see four trailblazers in AI, cybersecurity, and leadership.
  • The EWF Conference will feature panel discussions, roundtable workshops, and networking for female professionals in information security, risk management, and privacy.
  • We are confident that their insights will inspire the women in this industry to navigate complex challenges with confidence and resilience," says Linda R. Dolceamore, Leadership Conference Chair.

Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca® business to Alfasigma

Retrieved on: 
Monday, October 30, 2023
Linda, Euronext, International Financial Reporting Standards, Galapagos NV, International Air Transport Association code, Thirty-second Amendment of the Constitution Bill 2013, International, Committee, Filgotinib, Workforce, News, Acquisition, Related party transaction, UK, Statutory auditor, CET, Collaboration, CFO, European, Patient, Letter, Cryptocurrency, Pharmaceutical industry, Management, Commercial property, Audit, Pamlab, Galápagos Islands

Galapagos will pay up to €40 million by June 2025 to Alfasigma for Jyseleca® related development activities.

Key Points: 
  • Galapagos will pay up to €40 million by June 2025 to Alfasigma for Jyseleca® related development activities.
  • “Today’s news is the result of a thoughtful, in-depth analysis, and represents the successful conclusion of the strategic evaluation process for Jyseleca®.
  • The acquisition of Galapagos' Jyseleca® business represents another important milestone in Alfasigma's international transformation and growth path and fits perfectly with our Company's core business areas.
  • It is the intention in the contemplated transaction between Galapagos and Alfasigma that the amended Filgotinib Agreement will be assigned by Galapagos to Alfasigma.